Adoptive T-cell therapy of B-cell malignancies: Conventional and physiological chimeric antigen receptors

This publication has 45 references indexed in Scilit:

• Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
  New England Journal of Medicine, 2011
• In vivoInhibition of Human CD19-Targeted Effector T Cells by Natural T Regulatory Cells in a Xenotransplant Murine Model of B Cell Malignancy
  Cancer Research, 2011
• Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer
  Journal of Biomedicine and Biotechnology, 2010
• Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
  Leukemia, 2010
• Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
  Molecular Therapy, 2010
• Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor Eradication
  Molecular Therapy, 2010
• 4-1BB and CD28 Signaling Plays a Synergistic Role in Redirecting Umbilical Cord Blood T Cells Against B-Cell Malignancies
  Human Gene Therapy, 2010
• Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
  Molecular Therapy, 2009
• Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
  Proceedings of the National Academy of Sciences, 2009
• Redirecting Specificity of T-Cell Populations For CD19 Using the Sleeping Beauty System
  Cancer Research, 2008